This agreement aims to broaden access to advanced genomic technologies and enhance diagnostic accuracy.

SÃO PAULO, Feb. 23, 2025 — MGI Tech Co., Ltd. (“MGI”), dedicated to creating essential tools and technologies for life science innovation, has partnered with Oncoclínicas&Co, through its OC Medicina de Precisão (Genomics, Pathology, and Big Data laboratories), to improve access to state-of-the-art genomic testing and strengthen oncology diagnostic capabilities in Brazil.

The challenge of combating cancer is becoming increasingly critical in Brazil. A study¹ by the Federal University of São Paulo (UNIFESP) found that cancer-related deaths have surpassed cardiovascular disease deaths in 727 Brazilian cities. The research, published in The Lancet Regional Health – Americas, examined causes of death in Brazil’s 5,570 municipalities over 19 years. Therefore, monitoring neoplasms is vital for early detection and improved treatment effectiveness, leading to better clinical outcomes.

The primary goal of this partnership is to implement technological solutions that lower costs, accelerate diagnoses, and enable faster, more accurate therapeutic decisions. These advancements will foster a more efficient and equitable healthcare system, benefiting both patients and healthcare professionals.

“Genomics is revolutionizing our understanding and treatment of cancer. This partnership marks a significant milestone for oncology in Brazil by raising awareness among patients and professionals about the positive impact of oncogenetics on health, the potential of precision medicine, facilitating access to advanced technologies, and expanding genetic diagnostic capacity,” explains Carlos Carpio, Senior Commercial Director for MGI Latin America and General Manager for Brazil.

“This strategic alliance with MGI accelerates laboratory advancements in genomic medicine. By utilizing cutting-edge technology and expert support, our laboratory can greatly improve productivity, lower operational costs, and produce higher-quality data. This collaborative effort allows us to offer faster, more precise diagnostic testing, which ultimately enhances patient outcomes and accelerates the development of personalized treatments,” states Fernanda Koyama, Manager of Genomics and R&D at OC Medicina de Precisão, Oncoclínicas&Co.

Oncoclínicas&Co now features the DNBSEQ-G400, a medium-throughput genomic sequencer, enhancing their cancer diagnostic capabilities. Utilizing MGI’s DNBSEQ technology, this sequencer rapidly completes the sequencing process, enabling researchers to identify genetic predispositions to cancer, detect specific gene mutations, and determine effective oncology treatments through comprehensive tumor profiling.

The new technology is now available at Oncoclínicas&Co in São Paulo. In 2024, the institution’s Genomics department sequenced approximately one thousand samples per month, totaling around 12,000 for the year. Of these, 60% were germline panels for diagnosing cancer syndromes, and 40% were somatic panels focused on therapeutic decisions based on genomic biomarkers.

“Over the past two years, OC Medicina de Precisão has consistently invested in process efficiency and technology adoption to enhance our competitiveness. This allows us to serve a growing number of private patients, strengthen partnerships with pharmaceutical companies, and become the preferred choice for health insurers in precision medicine. We are contributing to broader public access to cutting-edge medicine and ensuring the sustainability of the healthcare system,” emphasizes Rodrigo Alvarenga, Operations Executive at Oncoclínicas&Co.

Expanding operations in Brazil

With the exponential growth of genomic research in Latin America, there is a rising demand for Next-Generation Sequencing tests in cancer diagnosis. MGI, operating in 100 countries, launched a Customer Experience Center in São Paulo in 2024. This center provides clinical laboratories and healthcare institutions with a space for demonstrations aimed at optimizing education and experience with the company’s technology. Highly skilled professionals offer certified training sessions, demonstrations, evaluations, and local support for new applications.

In the same year, MGI entered into strategic agreements with Dasa and Sabin Group to improve health diagnosis through genetic sequencing in Brazil. This partnership introduces new technologies for genetic testing to diagnose cancers, rare diseases, and other conditions with greater precision, thereby advancing personalized medicine in the country.

 

SOURCE MGI TECH

“`